Aktis Oncology, Inc. (AKTS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aktis Oncology, Inc.
Address
17 Drydock Avenue
Boston, MA 02210
United States of America (the)
Phone
617-461-4023
Sector
Healthcare
Industry
Biotechnology
Employees
79
First IPO Date
January 09, 2026
Key Executives
| Name | Title | Pay | Year Born |
| Matthew Roden | President, CEO & Director | 914,680 | N/A |
| Shulamit Ron-Bigger | Chief Operating Officer | 536,714 | 1981 |
| Paul L. Feldman | Chief Scientific Officer | 642,415 | 1962 |
| Akos Czibere | Chief Medical Officer | 676,930 | 1978 |
| Patrick A. Baeuerle | Co-Founder & Member of Scientific Advisory Board | 0 | 1958 |
| Kyle D. Kuvalanka | Chief Financial Officer | 0 | 1968 |
| Todd Foley | Co-Founder & Chairman | 0 | 1972 |
| Tyler Benedum | Chief Technical Officer | 0 | 1977 |
| Carlos Rodriguez | Executive Director of Corporate Development | 0 | N/A |
| Dasa Lipovsek | VP & Head of Lead Discovery | 0 | N/A |
Description
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
